Treatment of dry age-related macular degeneration

Ophthalmic Research

Volumn 52, Issue 3, 2014, Pages 107-115

  Querques, Giuseppe ^a,b   Rosenfeld, Philip J ^c   Cavallero, Edoardo ^b   Borrelli, Enrico ^b   Corvi, Federico ^b   Querques, Lea ^b   Bandello, Francesco M ^b   Zarbin, Marco A ^d  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d INSTITUTE OF OPHTHALMOLOGY AND VISUAL SCIENCE   (United States)

Author keywords

Age related macular degeneration; Drugs; Drusen; Geographic atrophy; Neurotrophic factors; Oxidative damage; Pathway; Stem cells; Treatment; Visual cycle

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; BCX 1470; BETA CAROTENE; BRIMONIDINE; CILIARY NEUROTROPHIC FACTOR; DOCOSAHEXAENOIC ACID; ECULIZUMAB; EMIXUSTAT; EYE DROPS; FENRETINIDE; GLATIRAMER; GSK 933776; ICOSAPENTAENOIC ACID; ISOTRETINOIN; LAMPALIZUMAB; LFG 316; MC 1101; MONOCLONAL ANTIBODY; NEUROPROTECTIVE AGENT; PF 4382923; POT 4; RAPAMYCIN; UNCLASSIFIED DRUG; XANTHOPHYLL; ZEAXANTHIN; GLUCOCORTICOID; LIPOFUSCIN;

AGE RELATED MACULAR DEGENERATION; DRY AGE RELATED MACULAR DEGENERATION; HUMAN; IMMUNOTHERAPY; MULTICENTER STUDY (TOPIC); NEUROPROTECTION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEM CELL TRANSPLANTATION; ANTAGONISTS AND INHIBITORS; GEOGRAPHIC ATROPHY;

ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; GEOGRAPHIC ATROPHY; GLUCOCORTICOIDS; HUMANS; LIPOFUSCIN; STEM CELL TRANSPLANTATION;

EID: 84910643156     PISSN: 00303747     EISSN: 14230259     Source Type: Journal    
DOI: 10.1159/000363187     Document Type: Review

References (105)

1. Zarbin MA, Rosenfeld PJ: Pathway-based therapies for age-related macular degeneration: an integrated survey of emerging treatment alternatives. Retina 2010;30:1350-1367.
2. Age-Related Eye Disease Study Research Group: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report No 8. Arch Ophthalmol 2001;119:1417-1436.
3. Omenn GS, Goodman GE, Thornquist MD, et al: Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Nat Cancer Inst 1996;88:1550-1559.
4. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 1994;330:1029-1035.
5. Moriarty-Craige SE, Adkison J, Lynn M, et al: Antioxidant supplements prevent oxidation of cysteine/cystine redox in patients with agerelated macular degeneration. Am J Ophthalmol 2005;140:1020-1026.
6. Brantley MA Jr, Osborn MP, Sanders BJ, et al: The short-term effects of antioxidant and zinc supplements on oxidative stress biomarker levels in plasma: a pilot investigation. Am J Ophthalmol 2012;153:1104-1109.e2.
7. Age-Related Eye Disease Study 2 Research Group: Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA 2013;309:2005-2015.
8. Age-Related Eye Disease Study 2 Research Group; Chew EY, Clemons TE, et al: Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No 3. JAMA Ophthalmol 2014;132:142-149.
9. Packer L: Antioxidant action of carotenoids in vitro and in vivo and protection against oxidation of human low-density lipoproteins. Ann NY Acad Sci 1993;691:48-60.
10. Bohm F, Tinkler JH, Truscott TG: Carotenoids protect against cell membrane damage by the nitrogen dioxide radical. Nat Med 1995;1:98-99.
11. Hammond BR Jr, Curran-Celentano J, Judd S, et al: Sex differences in macular pigment optical density: relation to plasma carotenoid concentrations and dietary patterns. Vision Res 1996;36:2001-2012.
12. Hammond BR Jr, Wooten BR, Snodderly DM: Cigarette smoking and retinal carotenoids: implications for age-related macular degeneration. Vision Res 1996;36:3003-3009.
13. Hammond BR Jr, Fuld K, Snodderly DM: Iris color and macular pigment optical density. Exp Eye Res 1996;62:293-297.
14. Hammond BR Jr, Wooten BR, Snodderly DM: Density of the human crystalline lens is related to the macular pigment carotenoids, lutein and zeaxanthin. Optom Vis Sci 1997;74:499-504.
15. Berendschot TT, Willemse-Assink JJ, Bastiaanse M, et al: Macular pigment and melanin in age-related maculopathy in a general population. Invest Ophthalmol Vis Sci 2002;43:1928-1932.
16. Landrum JT, Bone RA, Kilburn MD: The macular pigment: a possible role in protection from age-related macular degeneration. Adv Pharmacol 1997;38:537-556.
17. Bone RA, Landrum JT, Mayne ST, et al: Macular pigment in donor eyes with and without AMD: a case-control study. Invest Ophthalmol Vis Sci 2001;42:235-240.
18. Beatty S, Murray IJ, Henson DB, et al: Macular pigment and risk for age-related macular degeneration in subjects from a Northern European population. Invest Ophthalmol Vis Sci 2001;42:439-446.
19. Holz FG, Bellman C, Staudt S, et al: Fundus autofluorescence and development of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci 2001;42:1051-1056.
20. Kennedy CJ, Rakoczy PE, Constable IJ: Lipofuscin of the retinal pigment epithelium: a review. Eye 1995;9:763-771.
21. Lamb TD, Pugh EN Jr: Dark adaptation and the retinoid cycle of vision. Prog Retin Eye Res 2004;23:307-380.
22. Weng J, Mata NL, Azarian SM, et al: Insights into the function of Rim protein in photoreceptors and etiology of Stargardt's disease from the phenotype in abcr knockout mice. Cell 1999;98:13-23.
23. Beharry S, Zhong M, Molday RS: N-retinylidenephosphatidylethanolamine is the preferred retinoid substrate for the photoreceptorspecific ABC transporter ABCA4 (ABCR). J Biol Chem 2004;279:53972-53979.
24. Rattner A, Smallwood PM, Nathans J: Identification and characterization of all-trans-retinol dehydrogenase from photoreceptor outer segments, the visual cycle enzyme that reduces all-trans-retinal to all-trans-retinol. J Biol Chem 2000;275:11034-11043.
25. Maeda A, Maeda T, Imanishi Y, et al: Retinol dehydrogenase (RDH12) protects photoreceptors from light-induced degeneration in mice. J Biol Chem 2006;281:37697-37704.
26. Imanishi Y, Batten ML, Piston DW, et al: Noninvasive two-photon imaging reveals retinyl ester storage structures in the eye. J Cell Biol 2004;164:373-383.
27. Imanishi Y, Gerke V, Palczewski K: Retinosomes: new insights into intracellular managing of hydrophobic substances in lipid bodies. J Cell Biol 2004;166:447-453.
28. Redmond TM, Poliakov E, Yu S, et al: Mutation of key residues of RPE65 abolishes its enzymatic role as isomerohydrolase in the visual cycle. Proc Natl Acad Sci USA 2005;102:13658-13663.
29. Jin M, Li S, Moghrabi WN, et al: RPE65 is the retinoid isomerase in bovine retinal pigment epithelium. Cell 2005;122:449-459.
30. Moiseyev G, Chen Y, Takahashi Y, et al: RPE65 is the isomerohydrolase in the retinoid visual cycle. Proc Natl Acad Sci USA 2005;102:12413-12418.
31. Jang GF, Van Hooser JP, Kuksa V, et al: Characterization of a dehydrogenase activity responsible for oxidation of 11-cis-retinol in the retinal pigment epithelium of mice with a disrupted RDH5 gene. A model for the human hereditary disease fundus albipunctatus. J Biol Chem 2001;276:32456-465.
32. Farjo KM, Moiseyev G, Takahashi Y, et al: The 11-cis-retinol dehydrogenase activity of RDH10 and its interaction with visual cycle proteins. Invest Ophthalmol Vis Sci 2009;50:5089-5097.
33. Sparrow JR, Fishkin N, Zhou J, et al: A2E, a byproduct of the visual cycle. Vision Res 2003;43:2983-2990.
34. Radu RA, Han Y, Bui TV, et al: Reductions in serum vitamin A arrest accumulation of toxic retinal fluorophores: a potential therapy for treatment of lipofuscin-based retinal diseases. Invest Ophthalmol Vis Sci 2005;46:4393-4401.
35. Kuksa V, Imanishi Y, Batten M, et al: Retinoid cycle in the vertebrate retina: experimental approaches and mechanisms of isomerization. Vision Res 2003;43:2959-2981.
36. Quadro L, Blaner WS, Salchow DJ, et al: Impaired retinal function and vitamin A availability in mice lacking retinol-binding protein. EMBO J 1999;18:4633-4644.
37. Vogel S, Piantedosi R, O'Byrne SM, et al: Retinol-binding protein-deficient mice: biochemical basis for impaired vision. Biochemistry 2002;41:15360-15368.
38. Mata NL, Lichter JB, Vogel R, et al: Investigation of oral fenretinide for treatment of geographic atrophy in age-related macular degeneration. Retina 2013;33:498-507.
39. Sieving PA, Chaudhry P, Kondo M, et al: Inhibition of the visual cycle in vivo by 13-cis retinoic acid protects from light damage and provides a mechanism for night blindness in isotretinoin therapy. Proc Natl Acad Sci USA 2001;98:1835-1840.
40. Radu RA, Mata NL, Nusinowitz S, et al: Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration. Proc Natl Acad Sci USA 2003;100:4742-4747.
41. Maeda A, Maeda T, Golczak M, et al: Effects of potent inhibitors of the retinoid cycle on visual function and photoreceptor protection from light damage in mice. Mol Pharmacol 2006;70:1220-1229.
42. Akula JD, Hansen RM, Tzekov R, et al: Visual cycle modulation in neurovascular retinopathy. Exp Eye Res 2010;91:153-161.
43. Kubota R, Boman NL, David R, et al: Safety and effect on rod function of ACU-4429, a novel small-molecule visual cycle modulator. Retina 2012;32:183-188.
44. Anderson DH, Mullins RF, Hageman GS, et al: A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 2002;134:411-431.
45. Gehrs KM, Jackson JR, Brown EN, et al: Complement, age-related macular degeneration and a vision of the future. Arch Ophthalmol 2010;128:349-358.
46. Cherepanoff S, McMenamin P, Gillies MC, et al: Bruch's membrane and choroidal macrophages in early and advanced age-related macular degeneration. Br J Ophthalmol 2010;94:918-925.
47. Johnson LV, Leitner WP, Staples MK, et al: Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. Exp Eye Res 2001;73:887-896.
48. Hageman GS, Anderson DH, Johnson LV, et al: A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 2005;102:7227-7232.
49. Klein RJ, Zeiss C, Chew EY, et al: Complement factor H polymorphism in age-related macular degeneration. Science 2005;308:385-389.
50. Edwards AO, Ritter R 3rd, Abel KJ, et al: Complement factor H polymorphism and age-related macular degeneration. Science 2005;308:421-424.
51. Haines JL, Hauser MA, Schmidt S, et al: Complement factor H variant increases the risk of age-related macular degeneration. Science 2005;308:419-421.
52. Hughes AE, Orr N, Esfandiary H, et al: A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nat Genet 2006;38:1173-1177.
53. Skerka C, Lauer N, Weinberger AA, et al: Defective complement control of factor H (Y402H) and FHL-1 in age-related macular degeneration. Mol Immunol 2007;44:3398-3406.
54. Magnusson KP, Duan S, Sigurdsson H, et al: CFH Y402H confers similar risk of soft drusen and both forms of advanced AMD. PLoS Med 2006;3:e5.
55. Li M, Atmaca-Sonmez P, Othman M, et al: CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration. Nat Genet 2006;38:1049-1054.
56. Gold B, Merriam JE, Zernant J, et al: Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet 2006;38:458-462.
57. Spencer KL, Hauser MA, Olson LM, et al: Protective effect of complement factor B and complement component 2 variants in age-related macular degeneration. Hum Mol Genet 2007;16:1986-1992.
58. Yates JR, Sepp T, Matharu BK, et al: Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med 2007;357:553-561.
59. Ennis S, Jomary C, Mullins R, et al: Association between the SERPING1 gene and agerelated macular degeneration: a two-stage case-control study. Lancet 2008;372:1828-1834.
60. Maller JB, Fagerness JA, Reynolds RC, et al: Variation in complement factor 3 is associated with risk of age-related macular degeneration. Nat Genet 2007;39:1200-1201.
61. Fagerness JA, Maller JB, Neale BM, et al: Variation near complement factor I is associated with risk of advanced AMD. Eur J Hum Ge net 2009;17:100-104.
62. Thurman JM, Holers VM: The central role of the alternative complement pathway in human disease. J Immunol 2006;176:1305-1310.
63. Sohn JH, Kaplan HJ, Suk HJ, et al: Chronic low level complement activation within the eye is controlled by intraocular complement regulatory proteins. Invest Ophthalmol Vis Sci 2000;41:3492-3502.
64. Thurman JM, Renner B, Kunchithapautham K, et al: Oxidative stress renders retinal pigment epithelial cells susceptible to complementmediated injury. J Biol Chem 2009;284:16939-16947.
65. Wu Z, Lauer TW, Sick A, et al: Oxidative stress modulates complement factor H expression in retinal pigmented epithelial cells by acetylation of FOXO3. J Biol Chem 2007;282:22414-22425.
66. Zhou J, Jang YP, Kim SR, et al: Complement activation by photooxidation products of A2E, a lipofuscin constituent of the retinal pigment epithelium. Proc Natl Acad Sci USA 2006;103:16182-16187.
67. Engelbert M, Gilmore MS: Fas ligand but not complement is critical for control of experimental Staphylococcus aureus endophthalmitis. Invest Ophthalmol Vis Sci 2005;46:2479-2486.
68. Giese MJ, Mondino BJ, Glasgow BJ, et al: Complement system and host defense against staphylococcal endophthalmitis. Invest Ophthalmol Vis Sci 1994;35:1026-1032.
69. Aizuss DH, Mondino BJ, Sumner HL, et al: The complement system and host defense against Pseudomonas endophthalmitis. Invest Ophthalmol Vis Sci 1985;26:1262-1266.
70. Yehoshua Z, Alexandre De Amorim Garcia Filho C, Nunes RP, et al: Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study. Ophthalmology 2014;121:693-701.
71. Seddon JM, Yu Y, Miller EC, et al: Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration. Nat Genet 2013;45:1366-1370.
72. Regillo CD: Lampalizumab (anti-factor D) in patients with geography atrophy: the MAHALO phase II results. Presented at the 2013 Ann Meet Am Acad Ophthalmol, New Orleans, November 2013.
73. Wong WT, Dresner S, Forooghian F, et al: Treatment of geographic atrophy with subconjunctival sirolimus: results of a phase I/II clinical trial. Invest Ophthalmol Vis Sci 2013;54:2941-2950.
74. Landa G, Butovsky O, Shoshani J, et al: Weekly vaccination with Copaxone (glatiramer acetate) as a potential therapy for dry age-related macular degeneration. Curr Eye Res 2008;33:1011-1013.
75. Johnson LV, Leitner WP, Rivest AJ, et al: The Alzheimer's Aβ-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc Natl Acad Sci USA 2002;99:11830-11835.
76. Isas JM, Luibl V, Johnson LV, et al: Soluble and mature amyloid fibrils in drusen deposits. Invest Ophthalmol Vis Sci 2010;51:1304-1310.
77. Wang J, Ohno-Matsui K, Yoshida T, et al: Amyloid-β up-regulates complement factor B in retinal pigment epithelial cells through cytokines released from recruited macrophages/microglia: another mechanism of complement activation in age-related macular degeneration. J Cell Physiol 2009;220:119-128.
78. Ding JD, Johnson LV, Herrmann R, et al: Antiamyloid therapy protects against retinal pigmented epithelium damage and vision loss in a model of age-related macular degeneration. Proc Natl Acad Sci USA 2011;108:E279-E287.
79. Catchpole I, Germaschewski V, Hoh Kam J, et al: Systemic administration of A-beta mAb reduces retinal deposition of A-beta and activated complement C3 in age-related macular degeneration mouse model. PLoS One 2013;8:e65518.
80. Grunwald JE, Hariprasad SM, Du Pont J: Effect of aging on foveolar choroidal circulation. Arch Ophthalmol 1998;116:150-154.
81. Grunwald JE, Metelitsina TI, Dupont JC, et al: Reduced foveolar choroidal blood flow in eyes with increasing AMD severity. Invest Ophthalmol Vis Sci 2005;46:1033-1008.
82. Boltz A, Luksch A, Wimpissinger B, et al: Choroidal blood flow and progression of agerelated macular degeneration in the fellow eye in patients with unilateral choroidal neovascularization. Invest Ophthalmol Vis Sci 2010;51:4220-4225.
83. Ralston PG, Sloan D, Waters-Honcu D, Saigal S, Torkildsen G: A pilot, open-label study of the safety of MC-1101 in both normal volunteers and patients with early nonexudative age-related macular degeneration. Invest Ophthalmol Vis Sci 2010;51: E-Abstract 913.
84. Dunaief JL, Dentchev T, Ying GS, et al: The role of apoptosis in age-related macular degeneration. Arch Ophthalmol 2002;120:1435-1442.
85. Li Y, Tao W, Luo L, et al: CNTF induces regeneration of cone outer segments in a rat model of retinal degeneration. PLoS One 2010;5:e9495.
86. Tao W, Wen R, Goddard MB, et al: Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Invest Ophthalmol Vis Sci 2002;43:3292-3298.
87. Zhang K, Hopkins JJ, Heier JS, et al: Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc Natl Acad Sci USA 2011;108:6241-6245.
88. Bok D, Yasumura D, Matthes MT, et al: Effects of adeno-associated virus-vectored ciliary neurotrophic factor on retinal structure and function in mice with a P216L rds/peripherin mutation. Exp Eye Res 2002;74:719-735.
89. Zeiss CJ, Allore HG, Towle V, et al: CNTF induces dose-dependent alterations in retinal morphology in normal and rcd-1 canine retina. Exp Eye Res 2006;82:395-404.
90. Lai RK, Chun T, Hasson D, et al: Alpha-2 adrenoceptor agonist protects retinal function after acute retinal ischemic injury in the rat. Vis Neurosci 2002;19:175-185.
91. Wolde Mussie E, Ruiz G, Wijono M, et al: Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci 2001;42:2849-2855.
92. Wheeler L, Wolde Mussie E, Lai R: Role of alpha-2 agonists in neuroprotection. Surv Ophthalmol 2003;48(suppl 1):S47-S51.
93. Tatton W, Chen D, Chalmers-Redman R, et al: Hypothesis for a common basis for neuroprotection in glaucoma and Alzheimer's disease: anti-apoptosis by alpha-2-adrenergic receptor activation. Surv Ophthalmol 2003;48(suppl 1):S25-S37.
94. Zarbin M: The promise of stem cells for agerelated macular degeneration and other retinal degenerative diseases. Drug Discov Today Ther Strateg 2012.
95. Melville H, Carpiniello M, Hollis K, et al: Stem cells: a new paradigm for disease modeling and developing therapies for age-related macular degeneration. J Transl Med 2013;11:53.
96. Sarks JP, Sarks SH, Killingsworth MC: Evolution of geographic atrophy of the retinal pigment epithelium. Eye (Lond) 1988;2:552-577.
97. Zhu D, Wu J, Spee C, et al: BMP4 mediates oxidative stress-induced retinal pigment epithelial cell senescence and is overexpressed in age-related macular degeneration. J Biol Chem 2009;284:9529-9539.
98. Shen JK, Dong A, Hackett SF, et al: Oxidative damage in age-related macular degeneration. Histol Histopathol 2007;22:1301-1308.
99. Casaroli-Marano RP, Zarbin MA: Cell-Based Therapy for Retinal Degenerative Disease. Basel, Karger, 2014.
100. Carr AJ, Vugler AA, Hikita ST, et al: Protective effects of human iPS-derived retinal pigment epithelium cell transplantation in the retinal dystrophic rat. PLoS One 2009;4:e8152.
101. Sugino IK, Sun Q, Wang J, et al: Comparison of FRPE and human embryonic stem cellderived RPE behavior on aged human Bruch's membrane. Invest Ophthalmol Vis Sci 2011;52:4979-4997.
102. Schwartz SD, Hubschman JP, Heilwell G, et al: Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 2012;379:713-720.
103. Sugino IK, Rapista A, Sun Q, et al: A method to enhance cell survival on Bruch's membrane in eyes affected by age and age-related macular degeneration. Invest Ophthalmol Vis Sci 2011;52:9598-9609.
104. Jones BW, Watt CB, Frederick JM, et al: Retinal remodeling triggered by photoreceptor degenerations. J Comp Neurol 2003;464:1-16.
105. Fairchild PJ: The challenge of immunogenicity in the quest for induced pluripotency. Nat Rev Immunol 2010;10:868-875.